Most new users don't blow up dramatically. They just spend 8 weeks running a protocol poorly and conclude it didn't work. Here are the seven most common reasons that happens — and how to avoid each one.
The most popular peptide on the consumer market. Tendon, ligament, and gut healing. The evidence is more mixed than the marketing — and way more interesting.
Both are GLP-1 drugs that dominate weight loss. The trial data is clear enough to call — but there's also one win for each side, and the equation is more nuanced than the headlines suggest.
Decades of Russian clinical research, telomerase activation, and almost zero mainstream coverage. Here's what the data actually shows and why it's gaining traction in the West.
Short answer: it depends entirely on the peptide, the dose, the source, and the user. The longer answer is the most practical thing we can offer. Here's the real risk landscape.
Peptides are short chains of amino acids that act as biological signals. Here's what that actually means for why compounds like BPC-157 are running, and why the category is bigger than the headlines suggest.
The same compound from two different vendors can be a different product entirely. Here's how the research peptide supply chain actually works, and what COA testing can and can't tell you.
The FDA's PCAC finalized its determination on four of the most widely-used research peptides — ending their legal availability through U.S. compounding pharmacies.
Across Europe, national medicines agencies have narrowed legal access to compounded peptide preparations. France, Germany, and the UK led with guidance restricting BPC-157, TB-500, and GH secretagogues from standard compounding pathways.
BPC-157 has accumulated over 30 years of animal research yet formal human trials have been absent. New trial registrations in Europe and early IND movement signal the compound is approaching the clinical evidence threshold.
The landmark SELECT trial published in the NEJM demonstrated for the first time that a weight-loss peptide drug reduces major cardiovascular events independent of diabetes treatment.
The FDA approved tirzepatide (Zepbound) on November 8, 2023 — the first dual GIP/GLP-1 receptor agonist for obesity. SURMOUNT-1 showed 22.5% mean weight loss at 15mg, the largest ever in a phase 3 trial.
PepVault Premium
60+ peptide entries, dosing tables, AI Coach, and every stack guide.
Everything referenced in these articles — in full detail, in one place.